Tuesday | Wednesday | Thursday | Friday | Saturday
6:45 am - 5:15 pm Registration - Main Lobby
7:00 am - 9:00 am Spotlight Session 7: Biology of Invasive Lobular and Endocrine Resistant Breast Cancer - Stars at Night Ballroom 1&2 - 3rd Level
Chair: Douglas Yee, MD
Masonic Cancer Center
University of Minnesota
Minneapolis, MN


Biology of lobular breast cancer
Christine Desmedt, PhD
Institute Jules Bordet
Brussels, BELGIUM

Endocrine resistant breast cancer 
Shom Goel, B Med Sci, MBBS, FRACP, PhD
Dana-Farber Cancer Institute
Boston, MA
7:00 am - 9:00 am Spotlight Session 8: What's New in Loco-Regional Therapy - Stars at Night Ballroom 3&4 - 3rd Level
Chair: Ismail Jatoi, MD, PhD
UT Health San Antonio
San Antonio, TX


De-escalation of axillary surgery
Emiel Rutgers, MD, PhD, FRCS
Netherlands Cancer Institute

Breast-conserving surgery, DCIS management
Carmen Bergom, MD, PhD
Medical College of Wisconsin
Milwaukee, WI
7:00 am - 9:00 am

POSTER SESSION 4 & continental breakfast – Hall 1




Circulating BioMarkers & ctDNA
Diagnostic Pathology



Tumor Cell and Molecular Biology


Genetics - Germline Changes
Genetics - Somatic Changes
Mammary Development and Differentiation
Immunology and Preclinical Immunotherapy
New Drugs and Mechanisms


  Prognostic and Predictive Factors  
  Prognostic Factors - Clinical Testing and Validation
  Epidemiology, Risk, and Prevention  
  Risk Factors and Modeling
  Psychosocial, QOL, and Educational Aspects  

Palliation and Pain Management
Psychosocial Aspects


  Advanced Endocrine Therapy
Adjuvant Endocrine Therapy
Neoadjuvant Endocrine Therapy
9:00 am - 9:45 am

DEBATE - Hall 3


Should All Women with Breast Cancer and Positive Lymph Nodes Receive Chemotherapy?
Chairman: Clifford A. Hudis, MD
American Society of Clinical Oncology
Alexandria, VA

Daniel F. Hayes, MD, FACP, FASCO
University of Michigan Rogel Cancer Center
Ann Arbor, MI

Harold Burstein, MD, PhD
Dana-Farber Cancer Institute, Harvard Medical School
Boston, MA

9:45 am - 11:30 am

Moderator: Giuseppe Curigliano, MD, PhD
European Institute of Oncology
Milan, ITALY

9:45 am

GS5-01. A randomized community-based trial of an angiotensin converting enzyme inhibitor, lisinopril or a beta blocker, carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving adjuvant trastuzumab

  Munster P, Krischer J, Tamura R, Fink A, Bello-Matricaria L, Guilin M.  University of California, San Francisco, CA; University of South Florida, Tampa, FL; University of Kentucky, Lexington, KY.
10:00 am

GS5-02. Cardiovascular function and the effect of exercise training during adjuvant breast cancer treatment.  Results from the EBBA-II trial 

  Thune I, Husøy A, Frydenberg H, Flote VG, Fjeldheim F, Bertheussen GF, Lundgren S, Lømo J, Wist EA, McTiernan A, Schlichting E.  The Cancer Center, Oslo University Hospital, Ullevål, Oslo, Norway; The Arctic University of Norway, Tromsø, Norway; Norwegian School of Sport Sciences, Oslo, Norway; St. Olav Hospital, Trondheim, Norway; Norwegian University of Science and Technology, Trondheim, Norway; St. Olavs University Hospital, Trondheim, Norway; Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Fred Hutchinson Cancer Research Center, Seattle, WA.
10:15 am

GS5-03. Lifestyle intervention and effect on disease-free survival in early breast cancer pts: Interim Analysis from the randomized SUCCESS C study

  Janni W, Rack BK, Friedl TWP, Müller V, Lorenz R, Rezai M, Tesch H, Heinrich G, Andergassen U, Harbeck N, Schochter F, De Gregorio A, Tzschaschel M, Huober J, Hepp P, Fehm TN, Schneeweiss A, Lichtenegger W, Blohmer J, Hauner D, Beckmann MW, Häberle L, Fasching PA, Hauner H.  University Hospital Ulm, Ulm, Germany; Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; Gynecological Clinic Lorenz/Hecker/Wesche, Braunschweig, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; Onkologie Bethanien, Frankfurt, Germany; Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany; Ludwig-Maximilians-University Munich, München, Germany; HELIOS University Hospital Wuppertal, Wuppertal, Germany; University Hospital, Heinrich Heine University, Düsseldorf, Düsseldorf, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; Charité - Universitätsmedizin Berlin, Campus Mitte and Benjamin Franklin, Berlin, Germany; Institute for Nutritional Medicine, Else Kröner-Fresenius-Center for Nutritional Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, München, Germany; University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-University Erlangen, Erlangen, Germany.
10:30 am GS5-04. Discussant
Jennifer Ligibel, MD
Dana-Farber Cancer Institute
Boston, MA
10:45 am

GS5-05. Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state

  Echeverria GV, Ge Z, Seth S, Jeter-Jones SL, Zhang X, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Lau R, Shao J, Sun Y, Bristow C, Carugo A, Ma X, Harris A, Wu Y, Moulder S, Symmans WF, Marszalek JR, Heffernan TP, Chang JT, Piwnica-Worms H.  The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX.
11:00 am

GS5-06. No survival benefit of chemotherapy escalation in patients with pCR and "high-immune" triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial

  Gluz O, Nitz U, Liedtke C, Prat A, Christgen M, Feuerhake F, Garke M, Grischke E-M, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Pelz E, Gebauer D, Paré L, Kates R, Wuerstlein R, Kreipe HH, Harbeck N.  West German Study Group, Moenchengladbach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Charité, Women's Clinic, Berlin, Germany; Hospital Clínic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Hannover Medical School, Institute of Pathology, Hannover, Germany; University Hospital Luebeck, Luebeck, Germany; University Clinics Tuebingen, Women's Clinic, Tuebingen, Germany; Practice Network Troisdorf, Troisdorf, Germany; Rotkreuz Clinics Munich, Breast Center, Munich, Germany; City Hospital Holweide, Breast Center, Cologne, Germany; Marien Hospital, Breast Center, Witten, Germany; Practice of Gynecology and Oncology, Hildesheim, Germany; University Clinics Essen, Women's Clinic, Essen, Germany; University Clinics Leipzig, Women's Clinic, Leipzig, Germany; St. Elisabeth Hospital, Breast Center, Cologne, Germany; Clinics Essen Mitte, Breast Center, Essen, Germany; Institute of Pathology, Viersen, Germany; Breast Center, University of Munich (LMU) and CCCLMU, Munich, Germany; University Hospital Cologne, Cologne, Germany.
11:15 am GS5-07.  International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study
  Hartkopf AD, Brucker SY, Taran F-A, Harbeck N, von Au A, Naume B, Pierga J-Y, Hoffmann O, Beckmann MW, Ryd[eacute]n L, Fehm T, Aft R, Montserrat S, Walter V, Rack B, Schuetz F, Borgen E, Ta M-H, Bittner A-K, Fasching P, Fernö M, Krawczyk N, Weilbaecher K, Margelí M, Hahn M, Jueckstock J, Domschke C, Bidard F-C, Kasimir-Bauer S, Schoenfisch B, Kurt AG, Wallwiener M, Gebauer G, Wallwiener D, Janni W, Pantel K.
10:45 am - 5:00 pm EXHIBITS - Hall 2
11:30 am - 12:00 pm

2018 AACR Outstanding Investigator Award in Breast Cancer Research, supported by the Breast Cancer Research Foundation - Hall 3

  Breast Cancer in Young Women: Understanding Differences to Improve Outcomes
Ann Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
12:00 pm - 1:00 pm BREAK
12:00 pm - 1:00 pm  NETWORKING WITH THE EXPERTS - Hall 2 


Ratna K. Vadlamudi, PhD
UT Health San Antonio
San Antonio, TX

Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

Fabrice André, MD, PhD
Institut Gustave Roussy
Villejuif, FRANCE

Matthew J. Ellis, MD, PhD
Baylor College of Medicine
Houston, TX


Sylvia Adams, MD
New York University
New York, NY

Jose Conejo-Garcia, MD, PhD
H. Lee Moffitt Cancer Center
Tampa, FL

Elizabeth Mittendorf, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Targeting DNA Repair

Judith Balmaña, MD, PhD
Vall D'Hebron Institute of Oncology
Barcelona, SPAIN

Alexander Bishop, DPhil
UT Health
San Antonio, TX

Andrew Tutt, MbChB, PhD
Institute of Cancer Research

1:00 pm - 2:00 pm

CASE DISCUSSION 2 - Stars at Night Ballroom 1&2 - 3rd Level

  Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX


Sunil Badve, MD
Indiana University
Bloomington, IN

Eun-Sil Shelley Hwang, MD, MPH
Duke University School of Medicine
Durham, NC

Nancy U. Lin, MD
Dana-Farber Cancer Center
Boston, MA

Julia Maues
Georgetown Breast Cancer Advocates
Washington, DC

Stacy Moulder, MD
UT MD Anderson Cancer Center
Houston, TX

Gillian Ross, MD, PHD
Royal Marsden Hospital
1:00 pm - 2:00 pm TRANSLATIONAL SCIENCE FORUM 2 - Stars at Night Ballroom 3&4 - 3rd Level

Interplay Between Breast Cancer Targeted Therapies and the Immune System
Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX

Beyond B cells: Targeting BCL-2 pro-survival proteins in breast cancer 
Geoffrey Lindeman, MBBS, FRACP, PhD
Walter and Eliza Hall Institute of Medical Research
Parkville, AUSTRALIA

Modulation of anti-tumor immunity using CDK4/6 inhibitors
Shom Goel, B Med Sci, MBBS, FRACP, PhD
Dana-Farber Cancer Institute
Boston, MA

2:15 pm - 3:15 pm



Over and Under Treatment: Getting It Right for Each Patient
Moderator: Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Overtreatment: First, do no harm
Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

Missed opportunities - The perils of under-treatment
Rachel A. Freedman, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

3:15 pm - 5:00 pm

Moderator: Fatima Cardoso, MD
Champalimaud Clinical Center

3:15 pm GS6-01. Surgical treatment after neoadjuvant systemic therapy in young women with breast cancer: Results from a prospective cohort study
  Kim HJ, Dominici L, Rosenberg S, Pak LM, Poorvu PD, Ruddy K, Tamimi R, Schapira L, Come S, Peppercorn J, Borges V, Warner E, Vardeh H, Collins L, King T, Partridge A. Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Stanford University, Palo Alto, CA; Beth Israel Deaconess Medical Center, Boston, MA; Massachusetts General Hospital, Boston; University of Colorado Cancer Center, Aurora, CO; Sunnybrook Health Science Center, Toronto, Canada.
3:30 pm

GS6-02. A randomized, double-blind, placebo-controlled trial of oxybutynin (Oxy) for hot flashes (HF): ACCRU study 5C-1603

Leon-Ferre RA, Novotny PJ, Faubion SS, Ruddy KJ, Flora D, Dakhil C, Rowland KM, Graham ML, Le-Lindqwister N, Loprinzi CL.  Mayo Clinic, Rochester, MN; St Elizabeth Physicians, Ft. Thomas, KY; Cancer Center of Kansas, Wichita, KS; Carle Cancer Center NCORP, Urbana, IL; Waverly Hematology Oncology, Cary, NC; Illinois Cancer Care, Peoria, IL.
3:45 pm

GS6-03. Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results

  Wagner LI, Gray RJ, Garcia S, Whelan TJ, Tevarweerk A, Yanez B, Carlos R, Gareen I, McCaskill-Stevens W, Cella D, Sparano JA, Sledge, Jr. GW, On behalf of the TAILORx study team.  Wake Forest School of Medicine, Winston Salem, NC; Dana-Farber Cancer Institute, Boston, MA; Northwestern University School of Medicine, Chicago, IL; McMaster University, Hamilton, ON, Canada; University of Wisconsin, Madison, WI; University of Michigan, Ann Arbor, MI; Brown University, Providence, RI; National Institutes of Health, National Cancer Institute, Bethesda, MD; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Stanford University Medical Center, Stanford, CA.
4:00 pm

GS6-04. Development and validation of a chemotherapy toxicity (Chemo Tox) risk score for older patients (Pts) with breast cancer (BC) receiving adjuvant/neoadjuvant treatment (Adjuvant Tx): A R01 and BCRF funded prospective multicenter study

  Hurria A, Magnuson A, Gross CP, Twe WP, Klepin HD, Wildes TM, Muss HB, Dotan E, Freedman R, O'Connor T, Dale W, Cohen HJ, Katheria V, Arsenyan A, Levi A, Kim H, Sun C-L.  City of Hope Comprehensive Cancer Center, Duarte, CA; James Wilmot Cancer Center, University of Rochester, Rochester, NY; Yale School of Medicine, New Haven, CT; Memorial Sloan Kettering Cancer Center, New York, NY; Wake Forest School of Medicine, Wake Forest Winston-Salem, NC; Washington University School of Medicine, St. Louis, MO; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Fox Chase Cancer Center, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Duke University Medical Center, Durham, NC.
4:15 pm

GS6-05. The impact of breast cancer surgery on quality of life: Long term results from E5103

  Rosenberg SM, O'Neill A, Sepucha K, Miller KD, Dang CT, Northfelt DW, Sledge GW, Schneider BP, Partridge AH.  Dana-Farber Cancer Institute, Boston, MA; ECOG-ACRIN Biostatistics Center, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Rochester, MN; Stanford University, Stanford, CA.
4:30 pm

GS6-06. Local therapy and quality of life outcomes in young women with breast cancer

  Dominici LS, Hu J, King TA, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Partridge AH, Rosenberg SM.  Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; Mayo Clinic, Rochester, MN; Harvard T.H. Chan School of Public Health, Boston, MA; Massachusetts General Hospital, Boston, MA; Stanford University Medical Center, Stanford, CA; University of Colorado, Denver, CO; Beth Israel Deaconess Medical Center, Boston, MA; Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
4:45 pm

GS6-07. Discussant
Patricia A. Ganz, MD
Jonsson Comprehensive Cancer Center
Los Angeles, CA

5:00 pm - 7:00 pm  Spotlight Session 9: Metastasis/Microenvironment - Stars at Night Ballroom 1&2 - 3rd Level
Chair: Morag Park, PhD
McGill Cancer Research Centre
Montreal, CANADA


Katherine Hoadley, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC

Morag Park, PhD
McGill Cancer Research Centre
Montreal, CANADA
5:00 pm - 7:00 pm

POSTER SESSION 5 & reception - Hall 1




Breast Imaging - Mammography
Breast Imaging - MRI



Tumor Cell and Molecular Biology


Drug Resistance
Endocrine Therapy and Resistance
Hormonal Factors and Receptors
Microenvironments - Stromal Epithelial Interaction
Epithelial-Mesenchymal Transition



Epidemiology, Risk and Prevention


Familial Breast Cancer - Genetic Testing
Molecular Genetics


  Prognostic and Predictive Factors  

Predictive Biomarkers for Endocrine Therapies
Biomarkers General


  Psychosocial, QOL, and Educational Aspects  
  Disparities and Barriers to Care 
Doctor-Patient Communications
Cost Effectiveness

Inflammatory Breast Cancer


  Ongoing Trials  
  New Agents
Targeted - CDK 4/6
Targeted - PARP
Targeted - PD-1
Targeted - PD-L1
Targeted - PI3K
Targeted - Proteasome
Targeted - TNBC Stem Cells
6:00 pm - 7:30 pm SPECIAL SESSION
Stars at Night Ballroom 3&4 - 3rd Level
View from the Trenches: What Will You Do On Monday Morning?
Moderator: Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Panel Members:
Matthew P. Goetz, MD
Mayo Clinic
Rochester, MN

Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Ruth O'Regan, MD
University of Wisconsin
Carbone Cancer Center
Madison, WI

Debra Patt, MD, MPH
Texas Oncology
Austin, TX

Meredith M. Regan, ScD
Dana-Farber Cancer Institute
Boston, MA

Hope S. Rugo, MD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Bárbara Segarra-Vázquez, DHSc
Patient Advocate 
San Juan, PR
Tuesday | Wednesday | Thursday | Friday | Saturday